Neuropathologic differences by race from the National Alzheimer's Coordinating Center
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Introduction: Compared to Caucasians, African Americans (AAs) have higher dementia prevalence, different genetic markers, and higher vascular risk factors. However, pathologic underpinnings are unknown. Methods: We used neuropathologic and clinical data on 110 AA and 2500 Caucasians who were demented before death. The groups were compared regarding demographics, cognition, apolipoprotein E (APOE) genotype, comorbidities, and clinical and neuropathologic characteristics. Results: AA and Caucasians differed in their demographics, cognition at the last visit before death, APOE genotype, presence of hypertension, primary clinical diagnoses, and AD, cerebrovascular disease (CVD), and other neuropathologies such as Lewy body disease (LBD). Discussion: AD, LBD, and CVD pathology were more common and TDP and frontotemporal lobar degeneration–tau less common in AA than in Caucasians. APOE accounted for most of the AD neuropathologic differences. If replicated, the observed differences in underlying neuropathology by race will be important for public health policy and recruitment for and interpreting of clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Morris, J. C., Weintraub, S., Chui, H. C., Cummings, J., DeCarli, C., Ferris, S., Foster, N. L., Galasko, D., Graff-Radford, N., Peskind, E. R., et al. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213865.09806.92 · Cited by 950
Self-citationTang, M.-X. (1998) · JAMA · doi:10.1001/jama.279.10.751 · Cited by 771
Genetic variation, classification and ‘race’
Jorde, L. B., & Wooding, S. P. (2004) · Nature Genetics · doi:10.1038/ng1435 · Cited by 637
Reitz, C., Jun, G., Naj, A., Rajbhandary, R., Vardarajan, B. N., Wang, L.-S., Valladares, O., Lin, C.-F., Larson, E. B., Graff-Radford, N. R., et al. (2013) · JAMA · doi:10.1001/jama.2013.2973 · Cited by 431
Self-citationRisk of Dementia Among White and African American Relatives of Patients With Alzheimer Disease
Green, R. C. (2002) · JAMA · doi:10.1001/jama.287.3.329 · Cited by 391
Mixed pathology is more likely in black than white decedents with Alzheimer dementia
Barnes, L. L., Leurgans, S., Aggarwal, N. T., Shah, R. C., Arvanitakis, Z., James, B. D., Buchman, A. S., Bennett, D. A., & Schneider, J. A. (2015) · Neurology · doi:10.1212/wnl.0000000000001834 · Cited by 236
TREM2 is associated with increased risk for Alzheimer’s disease in African Americans
Jin, S. C., Carrasquillo, M. M., Benitez, B. A., Skorupa, T., Carrell, D., Patel, D., Lincoln, S., Krishnan, S., Kachadoorian, M., Reitz, C., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0016-9 · Cited by 153
Self-citationTwo rare AKAP9 variants are associated with Alzheimer's disease in African Americans
Logue, M. W., Schu, M., Vardarajan, B. N., Farrell, J., Bennett, D. A., Buxbaum, J. D., Byrd, G. S., Ertekin‐Taner, N., Evans, D., Foroud, T., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.010 · Cited by 136
Self-citationFarrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Association of Apolipoprotein E Genotype and Alzheimer Disease in African Americans
Murrell, J. R., Price, B., Lane, K. A., Baiyewu, O., Gureje, O., Ogunniyi, A., Unverzagt, F. W., Smith-Gamble, V., Gao, S., Hendrie, H. C., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.3.431 · Cited by 108
A DESCRIPTIVE STUDY OF NEURITIC PLAQUES AND NEUROFIBRILLARY TANGLES IN AN AUTOPSY POPULATION
DeWOLFE MILLER, F., HICKS, S. P., D'AMATO, C. J., & LANDIS, J. R. (1984) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113897 · Cited by 70
Sandberg, G., Stewart, W., Smialek, J., & Troncoso, J. C. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00236-0 · Cited by 68
Cited by
Impact of multiple pathologies on the threshold for clinically overt dementia
Kapasi, A., DeCarli, C., & Schneider, J. A. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1717-7 · Cited by 739
“Indeed, in a study combining multiple cohorts from differing settings, the clinical diagnosis of Dementia with Lewy body disease (Lewy body dementia or Parkinson’s disease) did not differ between races [42].”
BackgroundAssessment of Racial Disparities in Biomarkers for Alzheimer Disease
Morris, J. C., Schindler, S. E., McCue, L. M., Moulder, K. L., Benzinger, T. L. S., Cruchaga, C., Fagan, A. M., Grant, E., Gordon, B. A., Holtzman, D. M., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4249 · Cited by 370
Gilmore‐Bykovskyi, A. L., Jin, Y., Gleason, C., Flowers‐Benton, S., Block, L. M., Dilworth‐Anderson, P., Barnes, L. L., Shah, M. N., & Zuelsdorff, M. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.09.018 · Cited by 295
Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Jellinger, K. A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1821-9 · Cited by 264
Kunkle, B. W., Schmidt, M., Klein, H.-U., Naj, A. C., Hamilton-Nelson, K. L., Larson, E. B., Evans, D. A., De Jager, P. L., Crane, P. K., Buxbaum, J. D., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3536 · Cited by 257
Self-citation
Metadata
- Authors
- Graff‐Radford, N. R., Besser, L. M., Crook, J. E., Kukull, W. A., & Dickson, D. W.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2016-04-16
- Volume
- 12
- Issue
- 6
- Pages
- 669-677
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2339593696
- Cited by
- 100
- References
- 13
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.